New Hope for Breast Cancer Patients as Life Extending Drug Now on NHS in England The National Institute for Health and Care Excellence's (NICE) decision to approve Enhertu, a life extending drug for breast cancer patients, brings hope to thousands of women with HER2 low metastatic breast cancer in England.
However, this reversal also underscores the devastating consequences of delayed access to effective treatments.
The approval raises questions about the complex interplay between pharmaceutical companies, government agencies, and patient advocacy groups.